+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the clinical effectiveness and safety of icotrokinra in adults with moderately to severely active Crohns disease, a long-term condition causing serious inflammation in the intestines. The study is a Phase 2b3 randomized, double-blind, placebo-controlled trial aiming to better understand how well icotrokinra works in treating this condition. Participants will receive one of several oral treatments daily during an initial 12-week induction phase either one of two doses of icotrokinra or a matching placebo. After Week 12, their response status will guide further treatment. Those responding to icotrokinra may be randomized to maintenance doses for up to 40 weeks, with some eligible to join a long-term extension study. Placebo recipients who respond may continue placebo or switch to icotrokinra under specific conditions. Throughout the trial, participants will undergo regular assessments to monitor clinical response, remission, and endoscopic healing at Weeks 12 and 40. Safety will be closely followed up to four weeks after the last dose. The study measures various outcomes including patient-reported remission, inflammatory markers, quality of life, and fatigue. Total participation may extend up to several months depending on treatment phase and eligibility for long-term follow-up.

Age: 18Years +All GendersPhase 2Phase 3
395 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of JNJ-78934804 compared to guselkumab in adults with moderately to severely active Crohns disease, a long-term and progressive intestinal condition. This Phase 3 study aims to assess how well these treatments work by measuring clinical and endoscopic remission at Week 48. The study is sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to receive either JNJ-78934804 or guselkumab, both given as subcutaneous injections. Treatment starts with induction doses at Weeks 0, 4, and 8, followed by maintenance doses every 4 weeks from Week 12 onward. Those meeting rescue criteria during the study may receive additional induction doses of JNJ-78934804 at Weeks 16, 20, and 24, then continue maintenance dosing from Week 28. After completing the double-blind phase at Week 48, participants who may benefit can join a long-term extension phase. During the study, participants will undergo assessments to measure clinical remission, endoscopic remission, and other outcomes like deep remission and corticosteroid-free remission at various time points. Researchers will monitor patient-reported outcomes, adverse events, and serious adverse events for up to approximately three years. The study involves regular evaluations of disease activity and safety to understand treatment effects and participant well-being over time.

Age: 18Years +All GendersPhase 3
287 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are studying XmAb942 in a combined Phase 1 and Phase 2 clinical trial involving healthy volunteers and participants with moderately to severely active ulcerative colitis UC. The study aims to evaluate the safety, how the body processes the drug, and how the drug affects the body in healthy individuals, followed by assessing XmAb942s effects in people with UC. This trial is randomized, double-blind, and placebo-controlled, designed to understand the treatments potential in UC. The study has three parts. Part A involves single ascending doses of XmAb942 or placebo given subcutaneously or intravenously to healthy volunteers. Part B includes multiple ascending doses administered intravenously to healthy volunteers. Part C enrolls participants with active UC to receive three different doses of XmAb942 or placebo during a 12-week induction period, followed by a 40-week maintenance period with a single XmAb942 dose, then a 36-week follow-up. Participants will attend scheduled visits for dosing and monitoring throughout the study. Researchers will assess safety by tracking adverse events in healthy volunteers and clinical remission in UC patients using the modified Mayo score and endoscopic evaluation. Additional blood tests will measure drug levels and effects. The total participation duration can extend up to about 72 weeks for UC patients, including treatment and follow-up periods.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
114 locations